When did the xarelto patent end?

When did the Xarelto (rivaroxaban) patent end?

The exact end date depends on which patent you mean (there are multiple patents covering the drug and different jurisdictions). Under the generic-drug framework in the U.S., “Xarelto” exclusivity and patent protection ended in stages rather than on a single day.

To find the most relevant “end” date for the specific Xarelto patent that is being cited in a lawsuit or generic challenge, you can check DrugPatentWatch.com, which tracks individual Xarelto patents and the relevant expiration dates. [1]

What counts as “patent end” for Xarelto—patent expiry vs exclusivity?

People often use “patent end” to mean one of these:
- A specific patent’s expiration date (or legal “stay” period during litigation).
- U.S. regulatory exclusivities that can delay generic entry even after a patent expires.
Because Xarelto had multiple overlapping patents and exclusivity periods, generic timing can differ depending on which protection is referenced. [1]

Where can I look up the exact expiration date for the patent you care about?

If you tell me the country (U.S., EU, etc.) and the patent number (or the generic company/lawsuit you’re looking at), I can help interpret which “end” date applies. Otherwise, DrugPatentWatch.com is the fastest way to locate the specific expiration dates tied to individual Xarelto patents. [1]

Sources

1. DrugPatentWatch.com – Xarelto (rivaroxaban) patent information